Experimental Drug May Cut Severe Asthma Attacks: Study

THURSDAY, Aug. 16 (HealthDay News) -- An experimental drug known as mepolizumab may reduce outbreaks by almost 50 percent in people with a type of hard-to-treat asthma, an early study finds.
About a third of people with severe asthma have what is called eosinophilic asthma, in which inflammatory cells called eosinophils cause swelling of lung airways. Standard asthma treatment with inhaled steroids isn't effective, so these patients take oral steroids, which have many side effects, the researchers explained.....

Read More: ivillage.com



GSK runs to PhIII with upbeat data on drug for severe asthma

GlaxoSmithKline ($GSK) generated positive results from a mid-stage trial for its experimental drug in patients with an uncommon form of asthma, giving the London drug giant confidence in advancing the program to Phase III development before the end of the year, Reuters reported. And early success of the antibody drug mepolizumab fuels Glaxo's efforts to roll ahead with multiple next-generation respiratory treatments.....

Read more: fiercebiotech.com



Glaxo’s Experimental Drug Halves Asthma Attacks in Study

Patients with a rare form of asthma who took an experimental GlaxoSmithKline Plc (GSK) drug experienced almost half the rate of attacks compared with those who took a placebo, according to a company-funded study.....

Read more: businessweek.com